Decision Dx®-SCC

Will My Squamous Cell Skin Cancer Spread?

Talking With Your Healthcare Professional About DecisionDx®-SCC
Introduction
If you have recently been diagnosed with squamous cell skin cancer (sometimes called squamous cell carcinoma), you may be eligible for a genomic test called DecisionDx®-SCC, a gene expression profile (GEP) test that can accurately determine the risk of your cancer spreading to other parts of your body. This information can help you and your healthcare team make more informed and individualized choices about treatment and follow-up care. This downloadable sheet can help guide the discussion with your healthcare professional to make a decision about whether the DecisionDx-SCC test is right for you.

More About DecisionDx-SCC
As with all cancers, one of the primary challenges for healthcare professionals in managing squamous cell skin cancer is predicting the course of their patients’ disease, or prognosis. Having an accurate picture of whether or not your cancer is likely to spread to other parts of your body is critical to determining the right treatment and follow-up care.

DecisionDx-SCC examines your skin tumor at the molecular level and predicts with a high degree of accuracy the likelihood it will metastasize (spread to your lymph nodes or other parts of your body). If you have squamous cell skin cancer and one or more risk factors you may be a candidate for DecisionDx-SCC. Traditional risk factors include (but are not limited to):

- Large Tumor Size - Tumors larger than 2 centimeters (about 3/4 inch) in diameter.
- Specific Tumor Locations - tumors on the ear, lip, cheek, temple, and other areas.
- Immunosuppression - Patients who have an immune system that is suppressed. This could be from medication related to a solid organ transplant or an inflammatory disease.
- Deep Tumors - Cancer cells moving down from the skin surface, deep into underlying tissue.
- Poorly Differentiated Grade - A specific tissue characteristic a doctor identifies using a microscope.
- Perineural Involvement - Tumors that have invaded spaces around nerves.

Is DecisionDx-SCC Right for You?
If you would like to learn whether the DecisionDx-SCC test is right for you, please discuss it with your doctor or health care team. Only your doctor can order DecisionDx-SCC for you.

To help you and your healthcare team decide if DecisionDx-SCC is right for you, answer the questions below and then take this to your next appointment.

Please check all that apply

- I have been diagnosed with squamous cell skin cancer.
- I may have one or more risk factors making me a good candidate for DecisionDx-SCC.
- I would like to have an individualized assessment of the likelihood of my cancer spreading to other parts of my body.
DecisionDx-SCC – Better Identifies the Risk of Metastasis in SCC

DecisionDx-SCC has been validated in an independent, prospectively designed, multi-center (33 centers) study with archival tissue of 420 patients with known 3-year outcomes. Multivariate analysis shows DecisionDx-SCC provides the strongest independent prognostic information in SCC patients with one or more high-risk factors.

DecisionDx-SCC identifies the molecular signature of an individual’s tumor and its likelihood of metastasis within 3 years. The test results are individualized to the patient’s tumor, which is classified as one of the following phenotypes based on its risk profile:

<table>
<thead>
<tr>
<th>Class</th>
<th>LOW RISK</th>
<th>MODERATE RISK</th>
<th>HIGH RISK</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>&lt;7% risk of metastasis; Less than half the general study population risk</td>
<td>20% risk of metastasis; Similar to the strongest traditional factors</td>
<td>≥50% chance of metastasis over the next three years</td>
</tr>
</tbody>
</table>

Simple Ordering Process

To order DecisionDx-SCC simply complete an order form or order online at www.castletestinfo.com. Castle Biosciences will work with your staff to assure availability of the proper materials for sample collection and shipping. Please contact Clinical Services at 866-788-9007, ext. #1, at least 1 week prior to collection of your first biopsy sample.